Nivolumab(Mabpharm)

纳武利尤单抗 (Mabpharm)

Report date: 2025/06/23 13:59:20

Base Information

Drug NameNivolumab(Mabpharm)
Drug Alias NameNivolumab biobetterCMAB819注射液CMAB8-19CMAB-819
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 inhibitors
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSinomab Bioscience Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTaizhou Mabtech Pharmaceutical Co LtdTaizhou Maibo Taike Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular
Inactive IndicationsSquamous Cell Carcinoma of Head and Neck

Other Information

ATC CodeN/A
Related LinksN/A